Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Dec 10, 2018 3:04am

113 Views

Post# 29090253

RE:Taimed's conference

Big thanks stock38

As mentioned that really clarifies the IV-push issue.

Its also good to read that taimed have lowered their expectations to something more in-line with theratech. I imagine thats good for maintaining a strong partnership between the two companies.

I think the manufacturing capacity is not something to get too concerned about now. If taimed is truely acting to correct any issues now then it seems to me they have given themselves a lot of spare time to get the issue sorted before it becomes a pressing problem.

Bullboard Posts

Changing Europe’s dependency on HREE from China